Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Elevated lactate levels in the cerebrospinal fluid associated with bacterial meningitis.

Bosworth A, Bhatt K, Nance A, Winzor G, Atabani SF.

J Infect. 2019 Jun 13. pii: S0163-4453(19)30184-7. doi: 10.1016/j.jinf.2019.06.004. [Epub ahead of print] No abstract available.

PMID:
31201818
2.

Cytomegalovirus viral load parameters associated with earlier initiation of pre-emptive therapy after solid organ transplantation.

Lumley S, Green C, Rafferty H, Smith C, Harber M, O'Beirne J, Jones G, Thorburn D, Marshall A, Shah T, Zuhair M, Rothwell E, Atabani S, Haque T, Griffiths P.

PLoS One. 2019 Jan 25;14(1):e0210420. doi: 10.1371/journal.pone.0210420. eCollection 2019.

3.

Outcomes and costs of single-step hepatitis C testing in primary care, Birmingham, United Kingdom.

Munang M, Smit E, Barnett T, Atherton C, Tahir M, Atabani SF.

Public Health. 2019 Jan;166:40-44. doi: 10.1016/j.puhe.2018.09.024.

PMID:
30448691
4.

Dried blood spot and mini-tube blood sample collection kits for postal HIV testing services: a comparative review of successes in a real-world setting.

Page M, Atabani SF, Wood M, Smit E, Wilson S, Atherton C, Davenport CF, Hartland D, Simpson M, Taylor S.

Sex Transm Infect. 2019 Feb;95(1):43-45. doi: 10.1136/sextrans-2018-053567. Epub 2018 Aug 2.

PMID:
30072393
5.

Seroprevalence of maternal HIV, hepatitis B, and syphilis in a major maternity hospital in North Kordofan, Sudan.

Elkheir SM, Babiker ZO, Elamin SK, Yassin MI, Awadalla KE, Bealy MA, Agab Eldour AA, Alloba FE, Atabani SF, Osman HK, Babiker AG, Herieka EA.

Int J STD AIDS. 2018 Nov;29(13):1330-1336. doi: 10.1177/0956462418784687. Epub 2018 Jul 27.

PMID:
30049254
6.

Novel tumour antigens and the development of optimal vaccine design.

Brentville VA, Atabani S, Cook K, Durrant LG.

Ther Adv Vaccines Immunother. 2018 Apr;6(2):31-47. doi: 10.1177/2515135518768769. Epub 2018 Apr 10. Review.

7.

Correction: Randomized Controlled Trials to Define Viral Load Thresholds for Cytomegalovirus Pre-Emptive Therapy.

Griffiths PD, Rothwell E, Raza M, Wilmore S, Doyle T, Harber M, O'Beirne J, Mackinnon S, Jones G, Thorburn D, Mattes F, Nebbia G, Atabani S, Smith C, Stanton A, Emery VC.

PLoS One. 2017 Sep 19;12(9):e0185298. doi: 10.1371/journal.pone.0185298. eCollection 2017.

8.

Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers.

Green AR, Aleskandarany MA, Ali R, Hodgson EG, Atabani S, De Souza K, Rakha EA, Ellis IO, Madhusudan S.

Cancer Immunol Res. 2017 Apr;5(4):292-299. doi: 10.1158/2326-6066.CIR-16-0195. Epub 2017 Mar 2.

9.

Resource impact of managing suspected Middle East respiratory syndrome patients in a UK teaching hospital.

Veater J, Wong N, Stephenson I, Kirk-Granger H, Baxter LF, Cannon R, Wilson S, Atabani S, Sahota A, Bell D, Wiselka M, Tang JW.

J Hosp Infect. 2017 Mar;95(3):280-285. doi: 10.1016/j.jhin.2016.12.010. Epub 2016 Dec 18.

PMID:
28131646
10.

Randomized Controlled Trials to Define Viral Load Thresholds for Cytomegalovirus Pre-Emptive Therapy.

Griffiths PD, Rothwell E, Raza M, Wilmore S, Doyle T, Harber M, O'Beirne J, Mackinnon S, Jones G, Thorburn D, Mattes F, Nebbia G, Atabani S, Smith C, Stanton A, Emery VC.

PLoS One. 2016 Sep 29;11(9):e0163722. doi: 10.1371/journal.pone.0163722. eCollection 2016. Erratum in: PLoS One. 2017 Sep 19;12 (9):e0185298.

11.

Active screening and surveillance in the United Kingdom for Middle East respiratory syndrome coronavirus in returning travellers and pilgrims from the Middle East: a prospective descriptive study for the period 2013-2015.

Atabani SF, Wilson S, Overton-Lewis C, Workman J, Kidd IM, Petersen E, Zumla A, Smit E, Osman H.

Int J Infect Dis. 2016 Jun;47:10-4. doi: 10.1016/j.ijid.2016.04.016. Epub 2016 Apr 23.

12.

Dried blood spot testing: an alternative to point-of-care testing in public venues?

Flavell S, Davison C, Anderson N, Burbidge N, Atabani S, Taylor S, White D.

Sex Transm Infect. 2015 Mar;91(2):115. doi: 10.1136/sextrans-2014-051684. Epub 2014 Sep 24. No abstract available.

PMID:
25253763
13.

Response to letter regarding "cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy".

Atabani SF, Emery VC, Smith C, Harber M, Thorburn D, Griffiths PD.

Am J Transplant. 2012 Oct;12(10):2859-60. doi: 10.1111/j.1600-6143.2012.04227.x. No abstract available.

14.

Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy.

Atabani SF, Smith C, Atkinson C, Aldridge RW, Rodriguez-Perálvarez M, Rolando N, Harber M, Jones G, O'Riordan A, Burroughs AK, Thorburn D, O'Beirne J, Milne RS, Emery VC, Griffiths PD.

Am J Transplant. 2012 Sep;12(9):2457-64. doi: 10.1111/j.1600-6143.2012.04087.x. Epub 2012 May 17.

15.

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial.

Griffiths PD, Stanton A, McCarrell E, Smith C, Osman M, Harber M, Davenport A, Jones G, Wheeler DC, O'Beirne J, Thorburn D, Patch D, Atkinson CE, Pichon S, Sweny P, Lanzman M, Woodford E, Rothwell E, Old N, Kinyanjui R, Haque T, Atabani S, Luck S, Prideaux S, Milne RS, Emery VC, Burroughs AK.

Lancet. 2011 Apr 9;377(9773):1256-63. doi: 10.1016/S0140-6736(11)60136-0.

16.

Immunotherapy and vaccination after transplant: the present, the future.

Emery VC, Einsele H, Atabani S, Haque T.

Hematol Oncol Clin North Am. 2011 Feb;25(1):215-29. doi: 10.1016/j.hoc.2010.11.014.

PMID:
21236399
17.

Forgotten, but not gone.

Sanchez E, Atabani SF, Kaplanova J, Griffiths P, Geretti AM, Haque T.

BMJ. 2010 Nov 24;341:c5246. doi: 10.1136/bmj.c5246. No abstract available.

PMID:
21106624
18.

CD25+ natural regulatory T cells are critical in limiting innate and adaptive immunity and resolving disease following respiratory syncytial virus infection.

Lee DC, Harker JA, Tregoning JS, Atabani SF, Johansson C, Schwarze J, Openshaw PJ.

J Virol. 2010 Sep;84(17):8790-8. doi: 10.1128/JVI.00796-10. Epub 2010 Jun 23.

19.

Immunotherapy and vaccination after transplant: the present, the future.

Emery VC, Einsele H, Atabani S, Haque T.

Infect Dis Clin North Am. 2010 Jun;24(2):515-29. doi: 10.1016/j.idc.2010.01.004. Review.

PMID:
20466281
20.

Pancreas allograft thrombosis following intravenous immunoglobulin administration to treat parvovirus B19 infection.

Muthusamy AS, Vaidya AC, Sinha S, Atabani SF, Haque T, Jones G, Cunningham J, Friend PJ.

Transpl Infect Dis. 2009 Oct;11(5):463-6. doi: 10.1111/j.1399-3062.2009.00419.x. Epub 2009 Jul 5.

PMID:
19594866
21.

A case for varicella vaccination in the immunosuppressed.

Holmes MV, Atabani SF, Khan N, Steiner K, Haque T, Slapak G.

BMJ Case Rep. 2009;2009. pii: bcr07.2008.0461. doi: 10.1136/bcr.07.2008.0461. Epub 2009 Mar 17.

22.

Immune activation and IL-12 production during acute/early HIV infection in the absence and presence of highly active, antiretroviral therapy.

Byrnes AA, Harris DM, Atabani SF, Sabundayo BP, Langan SJ, Margolick JB, Karp CL.

J Leukoc Biol. 2008 Dec;84(6):1447-53. doi: 10.1189/jlb.0708438. Epub 2008 Sep 19.

23.

Inhibition of TLR-4/MD-2 signaling by RP105/MD-1.

Divanovic S, Trompette A, Atabani SF, Madan R, Golenbock DT, Visintin A, Finberg RW, Tarakhovsky A, Vogel SN, Belkaid Y, Kurt-Jones EA, Karp CL.

J Endotoxin Res. 2005;11(6):363-8.

PMID:
16303092
24.

Association of CTLA4 polymorphism with regulatory T cell frequency.

Atabani SF, Thio CL, Divanovic S, Trompette A, Belkaid Y, Thomas DL, Karp CL.

Eur J Immunol. 2005 Jul;35(7):2157-62.

25.

Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105.

Divanovic S, Trompette A, Atabani SF, Madan R, Golenbock DT, Visintin A, Finberg RW, Tarakhovsky A, Vogel SN, Belkaid Y, Kurt-Jones EA, Karp CL.

Nat Immunol. 2005 Jun;6(6):571-8. Epub 2005 Apr 24.

26.

Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway.

Karp CL, Flick LM, Park KW, Softic S, Greer TM, Keledjian R, Yang R, Uddin J, Guggino WB, Atabani SF, Belkaid Y, Xu Y, Whitsett JA, Accurso FJ, Wills-Karp M, Petasis NA.

Nat Immunol. 2004 Apr;5(4):388-92. Epub 2004 Mar 21.

PMID:
15034576
27.

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.

Moorthy VS, Pinder M, Reece WH, Watkins K, Atabani S, Hannan C, Bojang K, McAdam KP, Schneider J, Gilbert S, Hill AV.

J Infect Dis. 2003 Oct 15;188(8):1239-44. Epub 2003 Sep 30.

PMID:
14551895
28.

Vigorous but short-term gamma interferon T-cell responses against a dominant HLA-A*02-restricted measles virus epitope in patients with measles.

Jaye A, Herberts CA, Jallow S, Atabani S, Klein MR, Hoogerhout P, Kidd M, van Els CA, Whittle HC.

J Virol. 2003 Apr;77(8):5014-6.

29.

Natural measles causes prolonged suppression of interleukin-12 production.

Atabani SF, Byrnes AA, Jaye A, Kidd IM, Magnusen AF, Whittle H, Karp CL.

J Infect Dis. 2001 Jul 1;184(1):1-9. Epub 2001 May 30.

PMID:
11398102
30.

Sex-associated differences in the antibody-dependent cellular cytotoxicity antibody response to measles vaccines.

Atabani S, Landucci G, Steward MW, Whittle H, Tilles JG, Forthal DN.

Clin Diagn Lab Immunol. 2000 Jan;7(1):111-3.

31.

Supplemental Content

Loading ...
Support Center